Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology, Inc. (Nasdaq: KURA) will report its third quarter 2022 financial results before U.S. markets open on November 3, 2022. Management will host a conference call at 8:00 a.m. ET to discuss the results and provide a corporate update. Kura is focused on precision medicines for cancer treatment, with a pipeline including Ziftomenib, currently in trials for acute myeloid leukemia, and Tipifarnib, which has Breakthrough Therapy Designation for HRAS mutant head and neck cancer. A live webcast will also be available for investors.
Kura Oncology has reported promising preliminary results from its Phase 1/2 KURRENT-HN trial, demonstrating the potential of the combination therapy of tipifarnib and alpelisib in treating HRAS and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). A notable case showed a patient achieving an 81% reduction in target lesions after one cycle of the combination therapy. The trial aims to assess the safety and efficacy of this combination, targeting about 45% of HNSCC tumors with actionable mutations.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer treatments, announced that CEO Troy Wilson will participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET. The presentation will be available for 90 days in the Investors section of Kura's website. The company is advancing several drug candidates, including Ziftomenib for acute myeloid leukemia and Tipifarnib for HRAS mutant head and neck cancer.
Kura Oncology reported its Q2 2022 financial results and highlighted significant advancements in its clinical programs. The company identified a recommended Phase 2 dose for ziftomenib, pending FDA review, and enrolled an additional 18 patients in the KOMET-001 trial targeting acute myeloid leukemia. They observed preliminary efficacy in the KURRENT-HN trial of tipifarnib with alpelisib. Kura holds $450 million in cash and equivalents, expected to fund operations through 2024.
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, will participate in the Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022. CEO Troy Wilson will be on a panel titled “Bullseye - Targeted Oncology – In with the New,” scheduled for 10:20 AM ET. A live audio webcast will be available on Kura's website, with a replay to follow. The company is advancing its pipeline, including Ziftomenib in a Phase 1b trial for relapsed AML, while Tipifarnib is in registration trials for HRAS mutant HNSCC.
Kura Oncology (Nasdaq: KURA) will announce its second quarter 2022 financial results on August 3, 2022, after U.S. market close. Following this, management will host a webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Key programs include Ziftomenib in a Phase 1b trial for AML, and Tipifarnib, which has received Breakthrough Therapy Designation for HRAS mutant HNSCC. The company is also advancing multiple trials to provide precision treatments for various cancer types.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that Troy Wilson, Ph.D., J.D., its CEO, will participate in three investor conferences:
- Virtual fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit on June 2, 2022.
- Fireside chat at the Jefferies Healthcare Conference in New York on June 8, 2022.
- Fireside chat at the JMP Securities Life Sciences Conference in New York on June 16, 2022.
Audio webcasts will be accessible on Kura's website.
Kura Oncology, Inc. (Nasdaq: KURA) has completed enrollment for the Phase 1b expansion cohorts of ziftomenib, with topline data expected in Q3 2022. The company anticipates initial patient dosing in the HRAS cohort of the KURRENT-HN trial and the KURRENT-LUNG trial by Q3 2022. As of March 31, 2022, Kura reported cash and equivalents totaling $480 million, projected to sustain operations through 2024. The company experienced a net loss of $32.5 million for Q1 2022, with R&D expenses rising to $20.9 million. Management will hold a conference call today to discuss the financial results and updates.
Kura Oncology (Nasdaq: KURA) announced that it will release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call with management will take place at 4:30 p.m. ET to discuss the results and provide a corporate update. The call can be accessed via phone or streamed online. Kura Oncology focuses on precision cancer treatments and has multiple clinical trials underway, including Ziftomenib for relapsed AML and Tipifarnib for HRAS mutant HNSCC.
Kura Oncology (KURA) presented new preclinical data at the AACR Annual Meeting, showcasing the potential of its farnesyl transferase inhibitor (FTI), tipifarnib, to delay drug resistance to osimertinib in EGFR mutant non-small cell lung cancer (NSCLC). The data indicate that tipifarnib successfully clears drug-tolerant cells and prevents relapse to osimertinib for six months in preclinical models, with no observed toxicity. The company plans to start a Phase I trial of tipifarnib with osimertinib in third-quarter 2022 and submit an IND for next-gen FTI KO-2806 by year-end.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
